- | Valneva
Valneva Says Its Covid Vaccine Beats AstraZeneca’s. Shares Are Surging.
American depositary receipts of Valneva jumped more than 30% Monday after the French biotech said that phase-3 trials of its Covid-19 vaccine VLA2001 had shown it triggered a stronger immune response and fewer side-effects than the shot of competitor AstraZeneca.
- | MeiraGTx
This Small Biotech Is Partnering With Johnson & Johnson. The Stock Could More Than Double.
Among them is MeiraGTx Holdings, shares of which fell from a 2019 peak of $30 to a recent $14, leaving its market capitalization below $600 million—and only a half-dozen analysts paying it heed.
- | 9 Meters
10 signs you may have celiac disease and when to see a doctor
People with celiac most likely experience diarrhea due to intestinal inflammation and damage caused by gluten, says Patrick Griffin, MD, gastroenterology specialist and Chief Medical Officer of 9 Meters Biopharma.
- | TFF Pharmaceuticals
Inhalable anti-COVID-19 antibody from TFF and Augmenta tamps down viral load in hamsters
When startup TFF Pharmaceuticals raised $14 million in a series A in 2018, its intention was to deploy its dry-powder drug-delivery technology toward making novel inhalable therapies for asthma, chronic obstructive pulmonary disease and other serious lung diseases. Then COVID-19 hit, and the company saw an opportunity to apply the platform to the emerging virus.
- | Ring Therapeutics
The Man Behind Moderna on What’s Next in Biotech
Don’t call Noubar Afeyan a venture capitalist. Sure, the 59-year-old founder and CEO of “venture creation” firm Flagship Pioneering has helped launch some 70 biotech companies in the past several decades. But Flagship both backs and performs the original scientific research of his portfolio companies. Its best-known launch is Moderna (ticker: MRNA), the vaccine-developer and world’s most valuable biotech company.
- | Portage Biotech
Portage Biotech (PRTG) CEO With A Company Overview
Portage Biotech (PRTG) researches and develops pharmaceutical and biotechnology products. Dr. Ian Walters, CEO of Portage Biotech, gives an overview of the company and the outlook for Portage Biotech. Portage Biotech partners with immune-oncology companies to guide novel cancer treatments through clinical development. Tune in to find out more.
- | Selecta Biosciences
Has Selecta found a way around gene therapy’s delivery problem? Takeda puts down $1B-plus to find out
Selecta’s platform makes use of a biodegradable nanoparticle that encapsulates the immunosuppressive drug rapamycin, and is designed to be given in conjunction with gene therapies to induce antigen-specific immune tolerance.
- | Cerevance
Question: In Fintech, How Much Is Too Much for Investors?
Brad Margus, chief executive of drug-discovery company Cerevance, said that lowering drug prices will especially hurt companies working on the hardest-to-crack diseases, where even though a drug that works would have a huge market, it’s nearly impossible to persuade investors to support new approaches. “The price controls now being pushed threaten to remove the chance for my investors to get those returns,” he said.
